CpG island hypermethylation-associated silencing of microRNAs promotes human endometrial cancer by unknown
Li et al. Cancer Cell International 2013, 13:44
http://www.cancerci.com/content/13/1/44PRIMARY RESEARCH Open AccessCpG island hypermethylation-associated silencing
of microRNAs promotes human endometrial
cancer
Bi-Lan Li, Wen Lu, Cong Lu, Jun-jie Qu, Ting-ting Yang, Qin Yan and Xiao-ping Wan*Abstract
Background: Endometrial cancer (EC) is the most common gynecologic malignancy, but the molecular events
involved in the development and progression of EC remain unclear. This study aimed to explore epigenetic
modification of genes and miRNAs involved in EC development.
Methods: Ishikawa and AN3CA cells were treated with 5’-Aza-2-deoxycytidine or histone deacetylase inhibitor. The
expression of miRNAs and related genes were detected by PCR and Western blot. Promoter methylation was
detected by bisulfite specific PCR sequencing. The proliferation, colony formation, cell cycle progression, migration
and invasion of EC cells were evaluated by MTT, soft agar assay, flow cytometry, wound healing and invasion assay,
respectively.
Results: Aberrant expression of miRNAs including miR-200b, miR-130a/b, miR-625 and miR-222 was associated with
tumorigenesis and metastasis in endometrial cancer. Silencing of miR-130b induced E-cadherin expression, while
ectopic expression of miR-130b and knockdown of DICER1 increased the expression of Vimentin, zeb2, N-cadherin,
Twist and Snail in EC cells. Furthermore, 5’-Aza-2-deoxycytidine and Histone deacetylase (HDAC) inhibitor inhibited
the proliferation, colony formation, migration and invasion of EC cells, accompanied by reduced MMP secretion.
Conclusions: Our study provides the first description of epigenetic modification of epithelial mesenchymal
transition associated genes and miRNAs in EC cells, which are extensively involved in the regulation of gene
expression and subsequent accumulation of malignant features of EC cells.
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Endometrial cancers are one of the most common
gynecological cancers in the United States, with over
35,000 women diagnosed each year. Endometrial
endometrioid carcinomas (EECs) represent 80-85% of all
endometrial cancers [1]. When diagnosed at an early
stage, the prognosis for EC has improved over recent
years [2]. However, for patients diagnosed with late-stage
disease they have an overall poor prognosis [3]. There-
fore, there is urgent need to further understand the* Correspondence: xiaopingwan61@gmail.com
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reproduction in any medium, provided the ormolecular mechanism underlying the development and
progression of EEC.
Recent evidence has suggested that epigenetic mecha-
nisms contribute to the development, progression and
metastasis of cancer including endometrial cancer [4,5].
These epigenetic changes occur apart from primary gen-
omic sequences and include DNA methylation, histone
modifications, and miRNA expression [6]. In human neo-
plasias, CpG island hypermethylation is associated with
transcriptional silencing of tumor suppressor genes in-
cluding genes that encode miRNAs, which are produced
by DICER1, a cytoplasmic RNase III enzyme [7]. miR-
130b hypermethylation was found in ovarian cancer tis-
sues as well as in drug-resistant cell lines [8].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as a critical step driving epithelial mesenchymal transition
(EMT) in various human cancers. The loss of E-cadherin
expression increases tumor invasiveness in vitro and
in vivo and also increases the resistance of cancer cells to
chemotherapeutic agents. Recent reports have implicated
a crucial role for the miR-200 family in the regulation
of E-cadherin transcriptional repressors zinc finger E-
box binding homeobox 1 (ZEB1) and zinc finger E-
box binding homeobox 2 (ZEB2) [9]. In addition, the
downregulation of DICER1 has been associated with
the miR-200 family-EMT pathway and tumor metasta-
sis, which indicates poorer prognosis [10].
Here we presented for the first time a comprehensive
analysis of miR-130 family and DICER1 expression in
endometrial cancer tissues, compared with normal endo-
metrium. In addition, with EC cells as experimental
model we explored the mechanism and functional con-
sequences of dysregulation of some miRNAs, whose ex-
pression was linked to aberrant DNA methylation and
histone modification and regulated the growth and inva-
sion of EC cells.
Materials and Methods
Cell culture and treatment
The human endometrial cell lines Ishikawa and AN3CA
were obtained from the Chinese Academy of Sciences
Committee Type Culture Collection cell bank. The cells
were grown in Dulbecco’s modified Eagle’s medium
(DMEM)/F12 (11030; Gibco, Auckland, New Zealand)
supplemented with 10% fetal bovine serum (FBS)
(16000–44; Gibco, Carlsbad, CA), 100 u/mL penicillin,
and 100 μg/mL streptomycin in a humidified atmos-
phere of 5% CO2/95% air at 37°C. The cells were treated
with 10 μM 5’-Aza-2-deoxycytidine (Sigma) or 10 μM
HDAC inhibitor:Trichostatin A (TSA) (Sigma).
Cell transfection
Cells were washed with PBS and transiently transfected
with 100 nM pre-miR-130b or anti-miR-130b with their
corresponding negative controls (miR negative control
#1 or anti-miR negative control#1; Applied Biosystems;
Foster City, CA, USA) in Opti-MEM (Invitrogen, Carlsbad,
CA, USA) using siPORT NeoFX transfection agent
(Applied Biosystems; Foster City, CA,USA) following
the manufacturer’s protocol. Medium was replaced 8 h
later. small interfering RNA (siRNA) expression vectors
targeting DICER1 were transiently transfected into AN3CA
and Ishikawa cells using lipofectamine 2000 following the
manufacturer’s instructions.
Quantitative real-time PCR
Fresh-frozen EEC tissue samples and normal endometrial
samples were obtained from patients at the Obstetrics andGynecology Department of Shanghai First People’s Hos-
pital, affiliated to Shanghai Jiao Tong University School of
Medicine. Following excision, tissue samples were imme-
diately snap-frozen in liquid nitrogen and stored at −80°C
until RNA extraction. Total RNA was extracted from the
tissues or cells using TRIzol RNA Isolation Reagents
(Invirogen). The cDNA was generated using Prime Script
RT reagent Kit (TaKaRa, Dalian, China). A 50 μL PCR
amplification of single-strand cDNA was performed with
40 cycles of denaturation (94°C) for 60 s, annealing (55°C)
for 30 s, and elongation (72°C) for 30 s using PerfectShot
Ex Taq (Loading Dye Mix) (DRR05TA; Takara, Dalian,
China). The primer sequences were as follows: DICER1
Forward TTCCAAGTCGGTTGATACTGG, Reverse TG
TTGATTGTGACTCGTGGAC; Zeb2(sip1) Forward AG
CAGGTAATCGCAAGTTCAA, Reverse AGTTTGGGC
ACTCGTAAGGTT; Vimentin Forward ATGCGTGAA
ATGGAAGAGAACT, Reverse CTCAGGTTCAGGGAG
GAAAAGT; E-cadherin Forward GCTACTHHAACAG
GGACACTTC, Reverse TTCTGCTGTGAAGGGAGAT
GTA; β-actin Forward CAG AGC AAG AGA GGC ATC C,
Reverse CTG GGG TGT TGA AGG TCT C
Real-time quantitative PCR of miRNAs was performed
using TaqMan assay (Applied Biosystems, Foster City,
USA). The relative fold change was calculated based on the
differences in Ct values (ΔCt) between fold change = 2ΔΔ-
Ct. Three biological and technical replicates were done for
each sample. All values were expressed as mean ± standard
deviation.
Bisulfite specific PCR sequencing
The miRNA sequences were analyzed by using miRBase
(http://microrna.sanger.ac.uk/) and the University of
California at Santa Cruz Human Genome Browser
(http://genome.cse.ucsc.edu). The CpG Island Searcher
Program was used to determine which miRNAs were
embedded in CpG islands. Genomic DNA was isolated
from cells using Trizol (Invitrogen), and 500 ng grnomic
DNA was bisulfite modified using the EZ DNA
Methylation-Gold Kit (Zymo Research, Irvine, CA)
according to the manufacturer’s protocols. Two proce-
dures were used. First, methylation status was analyzed
by bisulfite modified DNA sequencing of the corre-
sponding CpG islands. Six independent clones were ana-
lyzed. The PCR was performed using a Rotor-Gene 3000
with 45 cycles of denaturation (95°C) for 30 s and
annealing (53°C) for 60 s, and a final extension at 72°C
for 4 min. PCR products were subcloned into T-easy
vector for sequencing.
Western blot analysis
Cells were washed with ice-cold PBS and lysed in ice-
cold RIPA (Beyotime) on ice for 30 min. Total protein
was measured using Bio-Rad protein assay reagent
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was seperated by 10% PAGE gels and transfered to
Polyvinylidene Fluoride (PVDF) membranes. After wash-
ing with tris-buffered saline, the membranes were blocked
with 5% bovine serum albumin (BSA)/phosphate buffered
saline (PBS) for 1 h, incubated at 4°C overnight with
primary antibodies against DICER1 (1:1000 dilution,
ab39742, Abcam, UK), E-CADHERIN (1:1000 dilution,
CST, USA), VIMENTIN (1:1000 dilution, CST,USA),
ZEB2 (1:1000 dilution,Epitomics), Twist1 (1:1000 dilution,
Epitomics), Snail (1:1000 dilution, Epitomics), N-cadherin
(1:1000 dilution, CST, USA) and β-actin (1:1000 dilution,
4697s, CST, USA). The membranes were washed three
times with PBS and then incubated with peroxidase-
linked secondary antibody (1:10 000) for 1 h at room
temperature. The signals were developed using an ECL kit
(Pierce), scanned, and analyzed with Total Lab software.
The relative expression of target proteins was presented as
the ratio to β-actin.Figure 1 Epigenetic silencing of miRNAs and EMT-related genes by C
cancer cells. qRT-PCR analysis of miR-130b, miR-301a, and miR-200b expre
levels in Ishikawa and AN3CA cells treated with 10 μM 5'-aza-CdR and 10 μ
compared to DMSO treatment.Cell invasion assay
Cell invasion was assessed by using a BD BioCoat
Matrigel Invasion Chamber (BD Biosciences) according
to the manufacturer’s instructions. Cells (5 × 104 cells/ml)
were loaded into chamber inserts containing an 8 μm pore
size membrane with a thin layer matrigel matrix. Cells
migrating to the lower surface of the membrane during
48 h were fixed with 100% methanol. The membranes
were then stained with hematoxylin, scanned, and ana-
lyzed with an Aperio Scanscope System (Aperio Tech-
nologies, Vista, CA).
Flow cytometry of cell cycle
Cells were fixed with 70% ethanol for 72 h and stained with
25 μg/mL propidium iodide (PI, Boster) in fluorescence-
activated cell sorting buffer (PBS containing 0.1% bovine
serum albumin, 0.05% of Triton X-100, and 50 μg /mL
RNaseA) for 30 min at room temperature in the dark.,
the cells were analyzed by flow cytometry using apG hypermethylation, and histone modification in endometrial
ssion as well as DICER1, zeb2, CDH1, and vimentin mRNA expression
M TSA. Data were shown as fold change. * P < 0.05, ** P < 0.01,
Figure 2 Bisulfite specific PCR sequencing to assess CpG
islands of miR130b. Box plots showed the mean ± SD. A. Relative
methylation levels in Ishikawa cells treated with 5’-Aza-Cdr (10 μM)
for 48 h, TSA (10 μM) for 48 h, or 5’-Aza-Cdr for 48 h plus TSA for 24 h.
B. Relative methylation levels in AN3CA cells treated with 5’-Aza-Cdr
(10 μM) for 48 h, TSA (10 μM) for 48 h, or 5’-Aza-Cdr for 48 h plus TSA
for 24 h. (C) Different levels of methylation between normal
endometrium and EECs.
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in triplicate in three independent experiments.
Proliferation assay
Cells were cultured in phenolred-free medium containing
5% charcoal-stripped FBS (HyClone Laboratories; Logan,
Utah, USA). Cell proliferation was analyzed every 24 h via
colorimetric assay with 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) (SIGMA; St. Louis,
MO, USA). Absorbance at 490 nm was evaluated by a
Spectra Max 190 microplate reader (Molecular Devices;
Sunnyvale, CA, USA). Experiments were performed in
triplicate in three independent experiments.
Soft agar colony assay
Cells were seeded in 0.3% top agar in growth medium
over a layer of 0.6% agar in a 6-well plate at a density of
1 × 104 cells/well. After 3 weeks of incubation, colonies
with more than 50 cells were counted and photographed
with an inverted microscope. The assay was performed
at least three times in triplicate.
Statistical analysis
Each experiment was performed as least three times,
and data are shown as the mean ± SD where applicable,
and differences were evaluated using one-way ANOVA
for 3-group comparisons and t tests for 2-group compar-
isons. All statistical analyses were performed using SPSS
13.0 software package. P < 0.05 was considered to be sta-
tistically significant.
Results
Methylation status of miRNAs in human endometrial
cancer cells treated with demethylation agents and
histone deacetylase inhibitor
miR-130a/b, miR-200b, and miR-625 contain several
CpG sites in their upstream regulatory sequences. We
assessed the methylation status of these CpG islands in
both EECs and normal endometrium by bisulfite-specific
PCR sequencing. We detected hypomethylation of miR-
130b in EECs. After treatment with demethylation agents
for 72 h, the expression of miR-130b increased 36.8-fold
in Ishikawa cells and 29.6-fold in AN3CA cells (P < 0.01)
(Figure 1). Furthermore, following treatment with HDAC
inhibitor, the expression of miR-130b was upregulated
21.2-fold in Ishikawa cells and 23.3-fold in AN3CA cells.
Surprisingly, the methylation level was found to be mildly
decreased, suggesting a role for HDAC inhibition in
modulating the DNA methylation status. The EMT-
related genes, miR-200b, miR-130a, zeb2, and E-cadherin
were also upregulated by demethylating agents. Con-
versely, DICER1 and vimentin were downregulated by
these agents (Figure 1).We further examined whether miR-130b expression
was regulated by CpG methylation. Compared to normal
endometrium tissue, EECs displayed significantly lower
levels of methylation, and the level of miR-130b was
negatively correlated with CpG methylation (Figure 2).
To explore the mechanisms underlying the upregulation
of miRNAs in endometrial cancers, we examined the
methylation status of miR-130a, miR-130b, miR-625 and
miR-200b by bisulfite-specific PCR sequencing (Table 1).
These miRNAs were epigenetically regulated through
the associated CpG islands, and the methylation levels
were closely linked with the expression of these miRNAs
(Figure 2). We also performed bisulfite-specific PCR se-
quencing for DICER1 in Ishikawa cells and found that the
Table 1 Bisulfite specific PCR sequencing of miRNAs
GENE Celltype
Bisulfite specific PCR sequencing
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DICER1 (data not shown).
miR130b and DICER1 regulate EMT realted genes
We compared the expression of miR-130b and DICER1
between endometrial cancers and normal endometrium.
qRT-PCR analysis indicated that miR-130b was lower in
normal endometrium than in endometrial cancer while
DICER1 was higher in normal endometrium than in
endometrial cancer (Figure 3A). These data indicated
that miR-130b was inversely correlated with DICER1 ex-
pression at the mRNA level.
To understand the role of miR-130b and DICER1 in
the regulation of EMT, we manipulated the expression
of miR-130b and DICER1 in EC cells and examined the
effects on the expression of EMT-related genes such as
E-cadherin, Twist, Snail, N-cadherin, zeb2 and vimentin.
Ishikawa and AN3CA cells were transiently transfected
with anti-miR-130b inhibitor and anti-negative control
(anti-NC), along with DICER1 siRNA and siRNA nega-
tive control. The results showed that transfection of pre-
miR-130b upregulated vimentin, N-cadherin, Twist, zeb2
and Snail expression, but downregulated E-cadherin
expression. In contrast, transfection of DICER1 siRNA
downregulated E-cadherin expression (Figure 3B, C).
These results suggest that miR-130b and DICER1 have
opposite effects on the regulation of EMT.
5’-Aza-2-deoxycytidine and HDAC inhibitor regulate
biological behaviors of endometrial cancer cells
After incubation with 5’-Aza-2-deoxycytidine and HDAC
inhibitor for 48 h, the expression of DICER1, E-cadherin
and Vimentin were analyzed by Western blot. The expres-
sion of DICER1 and E-cadherin protein were up-regulated
significantly in the cells treated with 5’-Aza-2-deoxycytidineFigure 3 miR130b and DICER1 regulate EMT realted genes. A. The exp
The scatter plots indicated an inverse correlation between miR-130b and D
blots showing E-cadherin, N-cadherin, Twist1, Snail, Zeb2 and vimentin exp
miR130b or pre-miR130b.or HDAC inhibitor compared with the control, while the
expression of Vimentin was down-regulated significantly in
the cells treated with 5’-Aza-2-deoxycytidine (Figure 4A).
The proliferation assay showed that 5’-Aza-2-deoxycytidine
and HDAC inhibitor inhibited the growth of EC cells in
a time-dependent manner (Figure 4B). Flow cytometry
showed that in AN3CA and Ishikawa cells demethylation
agents caused an increase of cells in G0/G1 phase and a re-
duction of cells in S phase (Figure 4C and Tables 2 and 3).
We went on to investigate whether 5’-Aza-2-deoxycytidine
and HDAC inhibitor could inhibit anchorage-independent
growth, a hallmark of oncogenic transformation. The soft
agar assay showed that the colony formation of AN3CA
cells in soft agar was significantly inhibited by treatment
with 5’-Aza-2-deoxycytidine or TSA (Figure 4D).
Using transwell chambers precoated with Matrigel, we
examined the effect of demethylation agents and HDAC
inhibitor on the invasion of EC cells. AN3CA and
Ishikawa cells treated with demethylation agents and
HDAC inhibitor showed significantly decreased invasive-
ness compared with control and untreated cells (Figure 4E).
In contrast, the controls showed no effect. Similar results
were obtained in wound-healing assays with aggressive
AN3CA cells (Figure 4F).
Taken together, these results demonstrate that DNA
hypermethylation and histone deacetylation cooperate
to regulate the growth and invasion of endometrial can-
cer cells.
5’-Aza-2-deoxycytidine and HDAC inhibitor inhibit the
secretion of Matrix metalloproteinase 2 (MMP-2) and
Matrix metalloproteinase 9(MMP-9) in endometrial cancer
cells
To understand the mechanims by which DNA hyper-
methylation and histone deacetylation regulate the invasionression and correlation of miR-130b and DICER1 in clinical samples.
ICER1 mRNA expression, as determined by real-time PCR. B, C. Western
ression levels in AN3CA cells after transfection with DICER1 siRNA, anti-
Figure 4 5’-Aza-2-deoxycytidine and HDAC inhibitor regulate biological behaviors of EC cells. A. Western blots showing DICER1, E-
cadherin and vimentin expression levels in Ishikawa and AN3CA cells treated with 10 μM 5'-aza-CdR and 10 μM TSA. B. The proliferation of
AN3CA cells treated as indicated. C. The cell cycle prolifes of AN3CA cells treated as indicated. D. The colony formation of AN3CA cells treated as
indicated. E. Transwell invasion assay of AN3CA and Ishikawa cells treated as indicated. Representative images of AN3CA and Ishikawa cells were
shown (magnification × 200). Statistical analysis of the number of invaded Ishikawa and AN3CA cells. F. in vitro wound healing assay of AN3CA
cells. Photographs were taken at 0, 6 and 24 h after the wound was made.
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are positive regulators of cancer invasion. Using an ELISA
kit, we detected MMP-2 and MMP-9 levels in cultured su-
pernatants from AN3CA and Ishikawa cells treated with
5’Aza-Cdr (10–5 M) or TSA (10–5 M). The results showed
that the secretion of MMP-2 and MMP-9 was inhibited
by 5’Aza-Cdr or TSA (Figure 5). These data suggest that













24 h 10 μM+
HDAC inhibitor
for 24 h
G0-G1 40.3 63.4 64.2 65.2
S 20.7 17.31 16.64 16.01the invasion of endometrial cancer cells via the regulation
of MMPs.
Discussion
Although endometrial cancer consists of multiple tumor
types, EEC is the most common. DNA methylation, his-
tone modifications and miRNA regulation have emerged
















G0-G1 40.3 62.4 63.8 66.4
S 30.7 15.31 14.33 13.92
Figure 5 5’-Aza-2-deoxycytidine and HDAC inhibitor regulate the secretion of MMPs in EC cells. MMP-2 and MMP-9 secretion was
decreased significantly in cells treated with 5’Aza-Cdr (10–5 M) or TSA (10–5 M) The data are expressed as mean concentrations with SD. * P < 0.05,
** P < 0.01.
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expression of miRNAs including miR-200b, miR130a/b,
miR-625 and miR-222 was associated with tumorigenesis
and metastasis in endometrial cancer. We analyzed the
microRNA signatures associated with EC invasion and
determined their relationships with EMT markers
including E-cadherin, vimentin, and miR-200 family.
The loss of epithelial markers such as E-cadherin and
the acquisition of a mesenchymal phenotype such as
Vimentin were accompanied by the changes in the levels
of miRNAs.
We found dramatic differential expression of miR-
130b and the level of its CpG methylation associated
with EMT-related genes in endometrial cancer cells
treated with 5’-Aza-Cdr or TSA, compared to untreated
cells. Therefore, histone acetylation and DNA methyla-
tion may form a complex framework for epigenetic con-
trol of the development of EC. It has recently become
apparent that DNA methylation and histone modifica-
tion may be dependent on each other, and their cross-
talk is most likely mediated by biochemical interactions
between SET domain of histone methyltransferases and
DNA methyltransferases [11]. Here we showed that
HDAC inhibitor activated gene expression through thechanges in the histone methylation status, which is coor-
dinated with DNA methylation.
Notably, we found that 5’-Aza-CdR reversed the
hypermethylation of miR-130b promoter and inhibited
the maglinant behaviors of EC cells. These findings dem-
onstrate that particular DNA methylation of miRNAs is
associated with aggressive tumor behaviors and suggest
that CpG island hypermethylation-mediated silencing of
cancer-related miRNAs contributes to human tumorigen-
esis. An important issue of our study presented here is the
mechanism by which demethylating agents and HDAC in-
hibitors cause dysregulation of miR-130b expression. One
hypothesis is that HDAC inhibitor induces the increases
in chromatin acetylation, leading to the expression of a
factor that represses miRNA synthesis [6]. Alternatively,
HDAC inhibitors may disrupt the repressive transcrip-
tional complex that binds to miR-130b regulatory ele-
ments, leading to miR-130b up-regulation and consequent
inhibition of E-cadherin expression.
Our results showed that demethylation agents and
HDAC inhibitor inhibited the proliferation and colony for-
mation of EC cells, as well as the migration and invasion of
EC cells. EMT is a crucial event in tumor progression, and
it is associated with dysregulation of DICER1, E-cadherin
Li et al. Cancer Cell International 2013, 13:44 Page 9 of 9
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cadherin, Twist1, Snail and Zeb2. In this study we showed
that specific miRNAs, particularly miR-130a/b and miR-
200 family, were crucially involved in gene expression dur-
ing EMT and the subsequent accumulation of malignant
features. In particular, silencing of miR-130b induced E-
cadherin expression to inhibit EMT process, while ectopic
expression of miR-130b and knockdown of DICER1
increased the expression of Vmentin, zeb2, N-cadherin,
Twist and Snail to promote EMT process. A large body of
evidence suggests that the multigene regulatory capacity of
miRNAs is dysregulated and exploited in cancer and
miRNA signatures have been associated with clinical out-
comes of a variety of cancers including endometrial cancer
[12-15]. Recently, miR-152 was identified as a tumor
suppressor microRNA that was silenced by DNA
hypermethylation in endometrial cancer [16]. Consistent
with the epigenetic regulation of miRNAs we further
showed that demethylation agent or HDAC inhibitor
inhibited the secretion of MMP-2 and MMP-9 in EC cells,
which further proves that epigenetic regulation of miRNAs
play a role in the regulation of EMT and tumor metastasis
of EC.
In addition to conventional mechanisms of gene
inactivation, epigenetic changes of specific miRNAs, in-
cluding gain and loss of DNA methylation and altered
histone modifications, are considered hallmarks of hu-
man cancer. Reversal of DNA methylation and histone
modifications could potentially be therapeutic, as epi-
genetic modifications result in stable, heritable changes
in gene expression without altering genetic sequences or
gene function. Very recently, demethylating agent 5’-
aza-CdR was shown to synergize with progesterone ther-
apy to inhibit EC cell growth and invasion [17].Conclusions
To our knowledge, in this study we provide the first de-
scription of epigenetic modification of EMT associated
genes and miRNAs in EC cells. We show that specific
miRNAs along with DNA methylation and histone mod-
ifications are extensively involved in the regulation of
gene expression and subsequent accumulation of malig-
nant features of EC cells. These findings suggest that
miRNAs combined with demethylation agents and his-
tone modification agents could be potentially utilized for
endometrial cancer therapy.
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